Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 7/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28776122 | 0.86 | L3MBTL1 (0.54) | DUTENPP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL913298 | 0.82 | DUT (0.56) | DUTENPP1L3MBTL1PKM | |
| SCHEMBL13573329 | 0.82 | DUT (0.60) | DUTENPP1L3MBTL1PKM | |
| SCHEMBL7711032 | 0.80 | PKM (0.58) | DUTENPP1L3MBTL1PKM | |
| SCHEMBL17230537 | 0.80 | DUT (0.54) | DUTENPP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2983407 | 0.79 | ALDH1A1 (0.57) | DUTALDH1A1LMNAL3MBTL1PKM | |
| SCHEMBL12696994 | 0.79 | DUT (0.57) | DUTENPP1PKM | |
| SCHEMBL13671537 | 0.79 | DUT (0.57) | DUTENPP1ALDH1A1LMNAPKM | |
| SCHEMBL338055 | 0.79 | ALDH1A1 (0.56) | DUTENPP1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL7821648 | 0.78 | DUT (0.63) | DUTENPP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4916121-A | PHOSPHORYLASE INHIBITOR | TEIJIN LIMITED (JP) | 1990-04-10 | — | — | US | claimed |
| EP-0202056-B1 | ANTITUMOR AGENT | TEIJIN LIMITED (JP) | 1989-08-30 | — | — | EP | claimed |
| EP-0202056-A1 | Antitumor agent | TEIJIN LIMITED (JP) | 1986-11-20 | — | — | EP | claimed |
| JP-61254526-A | — | — | None | — | — | JP | disclosed |
| US-12419893-B2 | Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine | TOSK, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | SIERRA SCIENCES, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250222000-A1 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease | TOSK, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | SIERRA SCIENCES, LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250120956-A1 | Azole Compounds for Enhancing Telomerase Reverse Transcriptase (TERT) Expression | SIERRA SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250075198-A1 | TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES | BRANDEIS UNIVERSITY (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250049834-A1 | Methods and Compositions for Treating Mucositis | TOSK, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-1995012400-A1 | NOVEL ENZYME INHIBITORS, THEIR SYNTHESIS, AND METHODS FOR USE | UAB RESEARCH FOUNDATION (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1993002044-A1 | ACYCLIC 6-PHENYLSELENENYL PYRIMIDINE NUCLEOSIDES | BAKER CUMMINS PHARMACEUTICALS, INC. (US) | 1993-02-04 | — | — | WO | disclosed |
| US-4916121-A | PHOSPHORYLASE INHIBITOR | TEIJIN LIMITED (JP) | 1990-04-10 | — | — | US | disclosed |
| US-4916121-A | PHOSPHORYLASE INHIBITOR | TEIJIN LIMITED (JP) | 1990-04-10 | — | — | US | disclosed |
| US-4916121-A | PHOSPHORYLASE INHIBITOR | TEIJIN LIMITED (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0202056-B1 | ANTITUMOR AGENT | TEIJIN LIMITED (JP) | 1989-08-30 | — | — | EP | disclosed |
| EP-0202056-A1 | Antitumor agent | TEIJIN LIMITED (JP) | 1986-11-20 | — | — | EP | disclosed |
| EP-0202056-A1 | Antitumor agent | TEIJIN LIMITED (JP) | 1986-11-20 | — | — | EP | disclosed |
| JP-S61254526-A | ANTITUMOR AGENT FOR ORAL ADMINISTRATION | TEIJIN LTD | 1986-11-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | TERT, RNGTT, TERF2 | DUT 56/4885ENPP1 571/4885ALDH1A1 1015/4885 |
| US-12419893-B2 | Methods and compositions for maximizing the prevention and/or reduction of various maladies and drug side-effects using uridine | UMPS, UNG, UGDH | DUT 7/4885ENPP1 65/4885ALDH1A1 289/4885 |
| US-20250049834-A1 | Methods and Compositions for Treating Mucositis | UNG, UMPS, TYMP | DUT 5/4885ENPP1 51/4885ALDH1A1 367/4885 |
| US-20250075198-A1 | TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES | CDR2, TARDBP, CISD1 | DUT 4573/4885ENPP1 4220/4885ALDH1A1 4293/4885 |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | TERT, TELO2, POT1 | DUT 291/4885ENPP1 1718/4885ALDH1A1 565/4885 |
| US-20250120956-A1 | Azole Compounds for Enhancing Telomerase Reverse Transcriptase (TERT) Expression | TERT, ERG, TERF2 | DUT 52/4885ENPP1 960/4885ALDH1A1 578/4885 |
| US-20250222000-A1 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease | UPP1, UMPS, PNP | DUT 60/4885ENPP1 34/4885ALDH1A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.